Literature DB >> 8298321

Use of the activated clotting time in anticoagulation monitoring of intravascular procedures.

J Bowers1, J J Ferguson.   

Abstract

The activated clotting time first came into clinical use in the mid-1970s to guide the administration and reversal of heparin during cardiopulmonary bypass procedures. The explosive growth of cardiopulmonary bypass led to the development of automated techniques for measuring activated clotting times. Recent advances in the field of interventional cardiology have emphasized the importance of the coagulation cascade and the need for the prevention of thrombosis with anticoagulant drugs. The activated clotting time has emerged as an important means of monitoring and guiding heparin therapy during invasive intravascular procedures. This review focuses on the following topics: 1) the development of anticoagulation monitoring techniques; 2) current alternatives in bedside anticoagulation monitoring; and 3) the clinical application of activated clotting times outside surgery. Until prospective studies can establish appropriate "target" activated-clotting-time values for interventional procedures, procedural anticoagulation must be guided empirically. Nevertheless, the activated clotting time is extremely useful in the catheterization laboratory, for monitoring heparin therapy and the adequacy of anticoagulation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8298321      PMCID: PMC325107     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  40 in total

1.  The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies.

Authors:  R R PROCTOR; S I RAPAPORT
Journal:  Am J Clin Pathol       Date:  1961-09       Impact factor: 2.493

2.  Sensitivity of the Azure heparin assay and comparisons with activated clotting time and whole blood partial thromboplastin time.

Authors:  S O Salley; G C Whittlesey; S M Smith; M D Klein
Journal:  ASAIO Trans       Date:  1990 Jul-Sep

3.  Strategies for acute occlusion after coronary angioplasty.

Authors:  L F Satler; M B Leon; K M Kent; A D Pichard
Journal:  J Am Coll Cardiol       Date:  1992-04       Impact factor: 24.094

4.  Variability of the activated coagulation time.

Authors:  G P Gravlee; L D Case; K C Angert; A T Rogers; G S Miller
Journal:  Anesth Analg       Date:  1988-05       Impact factor: 5.108

5.  Limit(ation)s for ACT.

Authors:  D R Jobes; N Ellison; F W Campbell
Journal:  Anesth Analg       Date:  1989-07       Impact factor: 5.108

6.  Monitoring heparin therapy in hemodialysis. A report on the activated whole blood coagulation time tests.

Authors:  J E Congdon; C G Kardinal; J D Wallin
Journal:  JAMA       Date:  1973-12-24       Impact factor: 56.272

7.  Heparin resistance prior to cardiopulmonary bypass.

Authors:  E F Anderson
Journal:  Anesthesiology       Date:  1986-04       Impact factor: 7.892

8.  Binding and endocytosis of heparin by human endothelial cells in culture.

Authors:  T Bârzu; P Molho; G Tobelem; M Petitou; J Caen
Journal:  Biochim Biophys Acta       Date:  1985-05-30

9.  Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage.

Authors:  B S Bull; W M Huse; F S Brauer; R A Korpman
Journal:  J Thorac Cardiovasc Surg       Date:  1975-05       Impact factor: 5.209

Review 10.  Anticoagulation: a surgical perspective.

Authors:  M O Perry
Journal:  Am J Surg       Date:  1988-02       Impact factor: 2.565

View more
  1 in total

1.  Fatal Ovarian Hemorrhage Associated With Anticoagulation Therapy in a Yucatan Mini-Pig Following Venous Stent Implantation.

Authors:  Sophie Boorman; Hope Douglas; Bernd Driessen; Matthew J Gillespie; Thomas P Schaer
Journal:  Front Vet Sci       Date:  2020-01-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.